An interventional study of AI-Assisted Video-Based Diabetes Education in Type 1 Diabetes Mellitus, sponsored by Yuzuncu Yil University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Yuzuncu Yil University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey — 15 open to participants now, 17 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Turkey.
Among the 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey, this one is the 21st largest by planned enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2026, is one of 39 with no phase, reaches primary completion later than 14 of the 16 other live ones, and was the 77th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →15 of the 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 8–12
Istanbul University · Sites in Turkey
Ages 10–18 · Women only
Gazi University · Sites in Turkey
Ages 9–18
KTO Karatay University · Sites in Turkey
Ages 8–12
Biruni University · Sites in Turkey
Ages 9–18
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.
This study: 13 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 58 across the 49 interventional studies, 120 across the 28 observational. Of the 59 that completed or were terminated, 7 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 77 have an industry lead sponsor. The 10 most frequent:
Yuzuncu Yil University is the lead sponsor of 79 studies on the registry; 20 are open to participants now.
Yuzuncu Yil University has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 1 with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07544368Istanbul UniversityMediterranean Diet and Oxidative Stress in Type 1 Diabetes (MEDOX-T1D) | 2026-12 |
| NCT07830082Gazi UniversityDrawing and Writing Activities in Adolescents With Type 1 Diabetes | 2026-12-31 |
| NCT07946770Yuzuncu Yil UniversityAI-Assisted Diabetes Education for Children With Type 1 Diabetes | 2027-02-01 |
| NCT07670572Marmara UniversityThink-Find-Solve Activities for Insulin Self-Management in Type 1 Diabetes | 2027-04-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled study evaluates the effects of an artificial intelligence-assisted diabetes education video on quality of life, diabetes self-management skills, and glycemic control in children with type 1 diabetes mellitus. Participants are assigned to an intervention group receiving a 12-minute educational video through a Meta Quest 2 virtual reality headset or a control group receiving routine diabetes education and care. Outcomes are assessed at baseline and at three months using validated questionnaires and routinely recorded HbA1c values.
This single-center, parallel-group randomized controlled study investigates the effects of artificial intelligence-assisted video-based diabetes education on health-related quality of life, diabetes self-management skills, and glycemic control among children and adolescents diagnosed with type 1 diabetes mellitus.
The study is conducted at the Pediatric Endocrinology Outpatient Clinic of Van Training and Research Hospital in Türkiye. A target sample of 60 participants was determined through an a priori power analysis, allowing for potential attrition. Eligible participants are allocated to an intervention group or a control group using a computer-generated random sequence.
Participants in the intervention group receive a 12-minute diabetes education video developed using artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The video content was prepared using established diabetes management guidelines. Artificial intelligence tools were used to develop the educational script, images, digital avatar, and voice narration. The virtual reality headset is used to support attention to the educational material. Disposable protective eye pads and headset cleaning procedures are used between participants to reduce the risk of cross-contamination.
Participants in the control group continue to receive routine diabetes education and clinical care. Outcomes are evaluated at baseline and three months after the intervention. Diabetes-specific quality of life is assessed using the PedsQL 3.0 Diabetes Module, and diabetes self-management skills are assessed using the Life Management Skills Scale for Children With Diabetes. Glycemic control is evaluated using HbA1c values obtained from routinely collected medical records. No additional blood samples or laboratory tests are requested for research purposes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a 12-minute diabetes education video developed with artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The educational material addresses essential aspects of type 1 diabetes management and is based on established diabetes guidelines. The headset is used to support participant attention during the educational session.
Behavioral: AI-Assisted Video-Based Diabetes Education
Participants in the control group continue to receive routine diabetes education, follow-up, and clinical care provided by the pediatric endocrinology outpatient clinic. They do not receive the artificial intelligence-assisted educational video.
Participants in the experimental group receive a 12-minute diabetes education video developed using artificial intelligence tools. The educational content is based on established diabetes management guidelines and covers essential aspects of type 1 diabetes management. The video was prepared using ChatGPT, Gemini, HeyGen, ElevenLabs, and CapCut and is delivered through a Meta Quest 2 virtual reality headset to support attention and engagement. Disposable protective eye pads are used, and the headset is cleaned between participants to reduce the risk of cross-contamination.
Diabetes-Specific Quality of Life
Change in diabetes-specific quality of life from baseline to month 3, assessed using the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module. The 28-item instrument is scored on a 0-100 scale, with higher scores indicating better quality of life.
Time frame: Baseline and Month 3
Diabetes Self-Management Skills
Change in diabetes self-management skills from baseline to month 3, assessed using the Life Management Skills Scale for Children With Diabetes. The instrument contains 15 items covering diabetes management knowledge and coping skills. Higher scores indicate better life management skills.
Time frame: Baseline and Month 3
Glycemic Control (HbA1c)
Change in glycated hemoglobin (HbA1c) percentage from baseline to month 3. HbA1c values are obtained from medical records following routine physician-ordered clinical assessments. No additional laboratory tests are performed specifically for this study.
Time frame: Baseline and Month 3
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers due to privacy and confidentiality considerations, particularly because the study involves children and adolescents with type 1 diabetes mellitus. Data will be used only for the purposes approved by the ethics committee.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.
Of 848 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 10 months is below that.
Counting every sponsor, half of 953 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yuzuncu Yil University